PeptideKey News
Eli Lilly's SURMOUNT-MAINTAIN Phase 3 trial: tirzepatide patients regain 18% body weight within 12 months of stopping, with lean mass loss persisting.
This article is part of PeptideKey's evidence-based peptide research library covering 100+ compounds with lab-verified purity data.